Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $1.42 in the prior trading day, MaxCyte Inc (NASDAQ: MXCT) closed at $1.39, down -2.11%. In other words, the price has decreased by -$2.11 from its previous closing price. On the day, 0.72 million shares were traded. MXCT stock price reached its highest trading level at $1.43 during the session, while it also had its lowest trading level at $1.3725.
Ratios:
Our goal is to gain a better understanding of MXCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.71 and its Current Ratio is at 12.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Swirsky Douglas J bought 50,000 shares for $1.29 per share. The transaction valued at 64,500 led to the insider holds 161,811 shares of the business.
Masoud Maher bought 75,000 shares of MXCT for $102,915 on Aug 13 ’25. The President and CEO now owns 175,000 shares after completing the transaction at $1.37 per share. On Aug 13 ’25, another insider, Erck Stanley C, who serves as the Director of the company, bought 100,000 shares for $1.37 each. As a result, the insider paid 137,220 and bolstered with 398,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MXCT now has a Market Capitalization of 148183728 and an Enterprise Value of 40128240. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.15 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 1.122 whereas that against EBITDA is -0.816.
Stock Price History:
Over the past 52 weeks, MXCT has reached a high of $5.20, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is -29.36%, while the 200-Day Moving Average is calculated to be -54.40%.
Shares Statistics:
The stock has traded on average 878.75K shares per day over the past 3-months and 1489160 shares per day over the last 10 days, according to various share statistics. A total of 106.59M shares are outstanding, with a floating share count of 97.59M. Insiders hold about 8.46% of the company’s shares, while institutions hold 71.48% stake in the company. Shares short for MXCT as of 1753920000 were 3531269 with a Short Ratio of 4.02, compared to 1751241600 on 3438231. Therefore, it implies a Short% of Shares Outstanding of 3531269 and a Short% of Float of 3.3299996999999997.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate the current performance of MaxCyte Inc (MXCT) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.36 and -$0.46 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.4, with 6.0 analysts recommending between -$0.33 and -$0.47.
Revenue Estimates
6 analysts predict $8.37M in revenue for the current quarter. It ranges from a high estimate of $9M to a low estimate of $7.61M. As of the current estimate, MaxCyte Inc’s year-ago sales were $8.16MFor the next quarter, 6 analysts are estimating revenue of $9.03M. There is a high estimate of $9.5M for the next quarter, whereas the lowest estimate is $8.06M.
A total of 7 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $37.4M, while the lowest revenue estimate was $34.57M, resulting in an average revenue estimate of $36.4M. In the same quarter a year ago, actual revenue was $38.63MBased on 7 analysts’ estimates, the company’s revenue will be $41.79M in the next fiscal year. The high estimate is $44.66M and the low estimate is $39.66M.
